Advanced pancreatic cancer exhibits a high mortality rate and currently no effective therapy exists for it. Our findings may encourage the development of novel strategies and drugs to target HIF-1-active cells in advanced pancreatic cancer. One such strategy we have developed is the prodrug POP33, which selectively induces apoptosis of is the major transcriptional activator of hypoxia-responsive genes and intratumoral hypoxia is associated with increased risk of metastasis. However, the behavior of the cells having HIF-1 activity during the malignant progression in pancreatic cancer has not been tested.
Introduction
Pancreatic cancer is one of the most lethal solid tumors of the gastrointestinal tract. The high mortality rate of pancreatic cancer is due to the high incidence of metastatic disease at the time of diagnosis, a fulminant clinical course, and the lack of adequate systemic therapies. Peritoneal and extrapancreatic seeding is observed during end-stage pancreatic cancer. Pancreatic cancer is characterized by extensive invasion into surrounding tissues and metastasis to distant organs, even at an early stage. The prognosis of patients is poor (1) and new systemic agents are urgently needed.
Intratumoral hypoxia is a major factor contributing to cancer progression (1) (2) (3) (4) . This situation is exacerbated by the high oxygen demands of rapidly proliferating tumor cells, poor lymphatic drainage resulting in high interstitial pressure, and shunting of blood through immature tumor vasculature (3) . The evidence for hypoxia in pancreatic cancers includes their characteristic avascular appearance on computed tomography (5) and low intratumoral oxygen tension measurements (6) . Furthermore, the expression of target genes of hypoxia-inducible factor 1 (HIF-1), the major transcription factor activated under hypoxic conditions, is elevated in pancreatic cancers (2, (7) (8) (9) (10) (11) . They include proangiogenic factors such as vascular endothelial growth factor and growth/survival factors such as insulin-like growth factor, and extracellular matrix remodeling proteins such as metalloproteinase-9 (12) . Thus HIF-1 activity may play a crucial role in malignant progression of pancreatic cancers.
Orthotopic implantation of human pancreatic cancer cell line SUIT-2 has been reported as a clinically relevant model showing an aggressive and malignant phenotype with liver metastasis, peritoneal dissemination, and ascites (13, 14) . Although pathological studies have demonstrated the progression of pancreatic cancer in this 5 model, the contribution of hypoxic/HIF-1-active tumor cells to the metastatic process has not been evaluated.
HIF-1 is a transcription factor composed of HIF-1α and HIF-1β subunits.
Under normoxic conditions, HIF-1α protein is degraded by ubiquitination and proteasomal degradation following hydroxylation of proline residues in the oxygen-dependent degradation (ODD) domain (15) . Under hypoxic conditions, HIF-1α protein accumulates and translocates to the nucleus where it heterodimerizes with HIF-1β to form an active transcription factor. More than 60 putative direct HIF-1 target genes have been identified and many of them are implicated in angiogenesis, invasion, and metastasis (12) . Furthermore, HIF-1 has been recognized as a major resistance factor for anti-cancer therapies such as chemotherapy (16) (17) (18) (19) and radiotherapy (20-22).
Thus HIF-1 activity is a hallmark of tumor malignancy.
We hypothesized, first, that the invasion and metastasis of pancreatic cancer is associated with hypoxia and increased HIF-1 activity and, second, that therapy targeting HIF-1-active cells would impair malignant progression. We developed and validated a fusion protein, TAT-ODD-Procaspase-3 (TOP3), to specifically eradicate HIF-1-active hypoxic cells (20, (23) (24) (25) (26) (27) (28) . TOP3 consists of three domains. The TAT protein-transduction domain (PTD) efficiently delivers the fusion protein into cells in vivo (29). The ODD domain contains a VHL-mediated protein destruction motif from the human HIF-1α protein that confers hypoxia-dependent stabilization to the fusion protein (25) . The procaspase-3 domain is an inactive proenzyme form of human caspase-3 that is activated by preexisting apoptotic signals in hypoxic cells.
Here we report a newly developed fusion protein POP33, which has a novel PTD that mediates significantly higher protein transduction activity than TAT-PTD. We 6 examined the activity of PP33 in a clinically relevant orthotopic model ofr pancreatic cancer. We serially monitored HIF-1-active cancer cells with a bioluminescence photon counting device and demonstrated their involvement in local invasion and metastasis.
POP33 significantly increased caspase-3 activity, suppressed peritoneal dissemination, and prolonged survival. These results indicate that HIF-1 activity plays a crucial role in malignant progression and support the use of drugs targeting HIF-1 for the treatment of pancreatic cancer. 
Materials and Methods

Cell culture and isolation of SUIT-2/EF-Luc and SUIT-2/HRE-Luc cells
The human pancreatic cancer cell line SUIT-2 was purchased from the American Type Culture Collection. SUIT2/EF-Luc and SUIT-2/HRE-Luc cells were isolated from a colony formed after transfection with plasmid pEF/Luc and pEF/HRE-Luc, respectively (24) by calcium phosphate method (30) and antibiotic selection. The cells were maintained at 37 o C in 5% FCS-Dulbecco's modified Eagle medium (Nacalai Tesque, Kyoto, Japan) supplemented with penicillin (100 units/ml) and streptomycin (100 μg/ml). Hypoxic cell cultures were performed in 5% CO 2 -1% O 2 in a multi-gas incubator (ASTEC, Fukuoka, Japan). were added to each well and 24 h later the plates were monitored by a plate reader photometer (optical density (OD) at 450 nm). The assay was repeated every day. The OD of each well was divided by the OD on day 1 to calculate the relative cell number.
Growth assay
SUIT2/EF-
The experiments were done in triplicate and results were presented as mean relative OD ± SEM. The experiment was repeated three times.
Luciferase activity Assay. 10 4 cells were seeded onto 24 wells plate and cultured over night, then further cultured in an ordinary CO 2 incubator or an hypoxic chamber BACLITE-1 (pO2 > 0.02%; Sheldon Manufacturing, Cornerlius, OR) for 18 h. The cells were lysed and their luciferase activity was measured as described previously (19) .
Western blot analysis
SUIT2/EF-Luc, SUIT-2/HRE-Luc, and parental SUIT-2 cells were cultured under hypoxic (1% O 2 ) or aerobic (20% O 2 ) conditions for 20 h and then cells were harvested and the cell lysates were analyzed by Western blotting as described previously (19) . The experiment was repeated three times. 
Preparation and analysis of recombinant EGFP proteins
Expression vector plasmids of PTD-EGFP fusion proteins encoding enhanced green florescent protein were constructed by inserting the cDNA fragments encoding PTD, which was prepared by annealing corresponding oligonucleotides, and EGFP, which was excised from pEF-EGFP (Promega Corp.), into plasmid pGEX-6P-3. Recombinant proteins were prepared as described previously (20) 
POP33 preparation and administration to mice
DNA sequences encoding PTD3 were prepared by annealing appropriate oligonucleotides and replaced the TAT-ptd sequence present in TOP3. POP33 fusion protein was prepared by described previously for TOP3 (23) . POP33 suspended in 10 mM Tris buffer (1 mg/ml) was intraperitoneally injected into tumor-bearing mice (5 mg/kg).
In vivo imaging of Caspase-3 activity
For preparation of Z-DEVD-Aminoluciferin, 10 mg of VivoGlo Caspase 3/7 substrate (Promega) was dissolved in 67 μl of surfactant mix (70 μl of Tween 80, 640 μl of PEG 400, and 290 μl of N,N-dimethylacetamide) and then added to 100 μl of 5% dextrose in water. The mixture was vortexed to make a homogenous solution and peritoneally injected into tumor-bearing mice (100 μl/mouse). Ten min after Z-DEVD-Aminoluciferin injection, the mice were imaged with IVIS.
Statistical analysis
The Kaplan-Meier method was used to determine survival curves and comparisons between the curves were done by log-rank test. The statistical analyses were done using SPSS 16.0 for windows and Excel. A p-value below 0.05 was considered statistically significant.
Results
Characterization of SUIT-2 pancreatic cancer cells with luciferase reporter genes
HIF-1α overexpression is one of the hallmarks of malignancy (32) . We hypothesized that HIF-1-activity represents an important driving force for invasion and metastasis. To test this hypothesis, we performed serial quantitative measurements of HIF-1 activity in xenografts derived from cancer cell lines stably transfected with plasmid p5HRE-luciferase (21), which expressed firefly luciferase under the control of a HIF-1-dependent promoter. We applied this system to a clinically relevant orthotopic model to determine the levels of HIF-1 activity during the progression of pancreatic cancer. We first established a stable human pancreatic cancer cell line, SUIT-2/HRE-Luc. The control cell line SUIT-2/EF-Luc constitutively expressed luciferase and thus the luciferase activity was proportional to the tumor mass (21) . The growth (Fig. 1A) and HIF-1α expression (Fig. 1B ) of these cell lines were similar. The luciferase activity in SUIT-2/HRE-Luc cells under hypoxic conditions was more than 100 times higher than under aerobic conditions (Fig. 1C) . Conversely, the luciferase activity in SUIT-2/EF-Luc decreased as pO 2 decreased (Fig. 1C) , reflecting the global inhibition of transcription and translation that occurs in response to hypoxia (33) .
In vivo imaging of the progression of pancreatic cancer
The orthotopic model using SUIT-2 cells has been extensively studied and well Although the time course of the increases in tumor mass (SUIT2/EF-Luc) and HIF-1 activity (SUIT2/HRE-Luc) were similar, increases in HIF-1 activity were delayed about a week compared to increases in tumor mass (Fig. 2BC) , suggesting that the HIF-1 activity corresponded to the development of hypoxic regions in the growing cancers.
Interestingly, the timing of increased bioluminescence associated with spread of cancer to the abdominal cavity, typically 11 to 13 days after transplantation, was the same for the tumor mass and HIF-1 activity (Fig. 2C) , indicating that the tumor cells invading to the abdominal cavity already had HIF-1-activity.
Peritoneal dissemination caused hypoxia in the abdominal cavity
In order to directly measure pO 2 in the abdominal cavity at different stages of tumor progression a PtiO 2 probe was inserted into the abdominal cavity. Real-time monitoring of pO 2 throughout the abdominal cavity was performed over 5 min. When tumor cells 13 were localized to the transplant site and no ascites was detected (Fig. 3A, left photon counts/sec/ROI) was detected throughout the abdomen, pO 2 was less than 10 mm Hg. Ascites fluid accumulated significantly when the HIF-1-specific bioluminescent signal was greater than 1 x 10 7 photon counts/sec/ROI. The pO 2 of ascites was also measured and was similar to the abdominal cavity (Fig. 3A) . HIF-1 activity was reciprocally correlated with oxygen tension in both the abdominal cavity and ascites (Fig. 3A) .
At the final stage of the pancreatic cancer, the ascites contained extremely high levels (between 1,000 and 2200 pg/ml) of VEGF, a prototypical HIF-1-target gene product. The serum levels of VEGF in control mice were 113.2 ± 30.8 pg/ml. These results confirm that hypoxia induces HIF-1 activity in this model. Together with Fig. 2 , these results suggest that HIF-1-active cancer cells invade locally and create hypoxic conditions during growth and dissemination throughout the abdominal cavity.
Pancreatic cancer cells with HIF-1 activity were also visualized by bioluminescent imaging post-mortem. Mice with fulminant ascites were dissected 13 min after D-luciferin injection and HIF-1 activity of xenografts in the abdominal cavity was directly examined by ex vivo imaging (Fig. 3Ba-e) . The average volume of ascites was 4.1 ml when mice died with fulminant ascites. Cells in the ascites, which were collected by centrifugation, also had high levels of luciferase activity (Fig. 3Bb ).
14 Bioluminescence was also detected in the intestines ( Fig. 3Ba and Fig 3Bc) , primary tumors in the pancreas (Fig. 3Bd) , and liver metastases (Fig. 3Be) . These data indicate that HIF-1-active tumor cells contribute to local invasion, metastasis and peritoneal dissemination.
Construction of a novel hypoxia-targeting protein drug
We hypothesized that if HIF-1-active cells play a crucial role during the progression of pancreatic cancer, eradication of these cells would suppress invasion and metastasis.
For eradication of HIF-1-active cells, we previously developed and validated a hypoxia-targeting prodrug, TOP3, which efficiently induced apoptosis and decreased HIF-1 activity in tumors (23, 24) , and significantly enhanced radiotherapy (20). To improve efficacy, we constructed POP33, which contains a novel protein transduction domain, PTD3, consisting of poly-lysine and non-charged amino acids (Fig. 4A) . To assess the membrane transduction function of PTD-fusion proteins, PTD3 (present in POP33) and TAT-ptd (present in TOP3) were fused to EGFP and their membrane transduction activity was assessed with a fluorescence microscopy and flow cytometry.
The fusion proteins had similar fluorescent intensity in vitro (Fig. 4B ).
SUIT-2/HRE-Luc cells were treated with PTD3-EGFP or TAT-ptd-EGFP for 30 min, and washed extensively. The cells were then trypsinized and their fluorescent intensity was quantified by flow cytometry (Fig. 4C) . The results indicate that PTD3 has more than five times higher cell penetrating activity than TAT-PTD.
In vivo caspase-3 activity induced by POP33 treatment
Apoptosis induction by TOP3 was previously observed in vitro (23, 25) and in tumor sections by TdT-mediated dUTP-biotin nick-end labeling (24) . To directly examine the ability of POP33 to increase caspase-3 activity in vivo, we used 15 z-DEVD-Aminoluciferin (34), a prosubstrate that is converted to a luciferase substrate when cleaved by caspase-3. POP33 or buffer alone was intraperitoneally injected into mice with various degrees of HIF-1-dependent bioluminescnece (Fig. 5A, upper panels) .
Six hours leter, z-DEVD-Aminoluciferin was injected and caspase-3 activity was determined (Fig. 5A, lower panels) . Caspase-3 activity increased as HIF-1 activity increased in both control and POP33-treated mice (Fig. 5A upper panels and Fig. 5B ).
However, in the POP33-treated mice, higher caspase-3-dependent bioluminescence was detected compared to control mice with similar levels of HIF-1-dependent bioluminescence (Fig. 5B) . These results indicate that the procaspase-3 domain in POP33 is cleaved, thereby increasing caspase-3 activity in HIF-1-active/hypoxic tumor cells.
POP33 suppressed peritoneal dissemination and improved survival
When total photon counts were approximately 1 x 10 5 photons/sec/ROI, mice were Based on these findings, we have pursued strategies to target hypoxic pancreatic cancer cells. PTD-ODD-Procaspase-3 fusion proteins must enter cells to induce apoptosis and thus PTD function is very important for their efficacy. To improve PTD function, we constructed PTD3, which consists of two polar amino acid sequences, a hydrophobic tryptophan-rich motif related to Pep-1 (37), and poly-Lys. PTD3 endowed the fusion protein with higher membrane penetrating activity than TAT-PTD sequences.
The precise mechanism of PTD3 membrane penetration is under investigation.
The significance of HIF-1 in pancreatic cancer has been suggested (8) (9) (10) (11) 38) .
HIF-1-targeting prodrug POP33 successfully suppressed local invasion and thus peritoneal dissemination. Hypoxia activates caspase-3 in cells to some extent in vivo as well as in vitro (23) (24) (25) . Here we directly demonstrated that it is also true in vivo by visualization of caspases-3 activity with a real-time imaging method; in untreated mice, cancer cells had some caspases-3 activity, which also increased as HIF-1 activity increased. PTD-ODD-Procaspase-3 increased the caspases-3 activity significantly 19 higher than the control (23) (24) (25) and enhanced apoptosis in vivo (23, 25) , suppressing the tumor growth (24) , metastasis (26) B. Representative images from the experiment described in Figure 6A .
C. Kaplan-Meier survival curves for the experiment presented in Figure 6A . 
Figure S2. The representative ex vivo images of pancreatic cancers
Typical ex vivo images of SUIT-2/HRE pancreatic cancers from the mice with indicated bioluminescence (photon counts/sec/ROI). Bar, 10 mm.
